ImmunityBio says Anktiva plus BCG showed durable survival and bladder preservation at 36 months in BCG-unresponsive bladder cancer patients.

“PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of ...

A combination of the antibody-drug conjugate enfortumab vedotin (Padcev) and the PD-1 inhibitor pembrolizumab (Keytruda) ...

An existing oral drug already used to treat lung cancer could help improve survival rates for bladder cancer patients, a new clinical trial by UK scientists has found. There are approximately 10,300 ...

Armed with new three-year data demonstrating the benefits of Anktiva in a specific patient subset, ImmunityBio is proving its ...

Combination therapy with nogapendekin alfa inbakicept and BCG achieved a 3-year DSS rate of 96% in BCG-unresponsive NMIBC ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa ...

Merck says Keytruda plus Padcev improved survival and response rates versus chemotherapy in a Phase 3 muscle-invasive bladder ...

LAS VEGAS -- Patients with high-risk, treatment-unresponsive non-muscle invasive bladder cancer (NMIBC) had an unprecedented response rate and disease-free survival (DFS) with an investigational ...

PADCEV plus KEYTRUDA is the first and only regimen to improve survival when used before and after standard of care (surgical cystectomy) in cisplatin-ineligible patients with muscle-invasive bladder ...

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase ...

Non-muscle invasive bladder cancer is cancer that’s only in the inner lining of your bladder. It hasn’t grown into the muscle wall. Your doctor may also call it superficial bladder cancer, urothelial ...